immune-related adverse events

You have access
Effect of Acid Suppressants on Adverse Events of Immune Checkpoint Inhibitors Using Real-world Databases
KEISUKE OKAMOTO, JURI TAKIZAWA, HINATA UEDA, KATSUYA NARUMI and MASAKI KOBAYASHI

Anticancer Research August 2025, 45 (8) 3287-3293; DOI: https://doi.org/10.21873/anticanres.17689
You have access
Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer
SATOSHI ANO, NORIHIRO KIKUCHI, SHINICHIRO OKAUCHI, TAKESHI NUMATA, RYOTA NAKAMURA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, TOMOHIRO TAMURA, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, TAKAYUKI KABURAGI, TAKEO ENDO, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research June 2024, 44 (6) 2725-2730; DOI: https://doi.org/10.21873/anticanres.17080
You have access
Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma
TOKO MACHIDA, KANAME SAKUMA, NOBUKAZU FUWA and AKIRA TANAKA

Anticancer Research March 2024, 44 (3) 993-1002; DOI: https://doi.org/10.21873/anticanres.16894
You have access
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
TOMOHIRO TAMURA, TAKESHI NUMATA, HIDETOSHI YANAI, RYOTA NAKAMURA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, SHINICHIRO OKAUCHI, NORIHIRO KIKUCHI, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, HIROAKI SATOH, HIROICHI ISHIKAWA, TAKAYUKI KABURAGI, TAKEO ENDO, TORU SAKAMOTO and NOBUYUKI HIZAWA

Anticancer Research October 2023, 43 (10) 4583-4591; DOI: https://doi.org/10.21873/anticanres.16652
You have access
Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC
KAZUHIRO SHIMOMURA, TEPPEI YAMAGUCHI, YUKO OYA, KOSAKU UCHIDA and KENTA MUROTANI

Anticancer Research December 2022, 42 (12) 5961-5969; DOI: https://doi.org/10.21873/anticanres.16106
You have access
The Effect and Tolerability of Second-line Chemotherapy Are Associated With Disease Control by Nivolumab Chemotherapy in Patients With Gastric Cancer
HIROSHI MATSUOKA, TOMOHIRO MIZUNO, MINAMI SAKAI, KAZUMITSU SUZUKI, AKIKO SERIZAWA, MASAYA NAKAUCHI, TSUYOSHI TANAKA, SUSUMU SHIBASAKI, TAKAHIRO HAYASHI and KOICHI SUDA

Anticancer Research October 2022, 42 (10) 4973-4980; DOI: https://doi.org/10.21873/anticanres.16004
You have access
An In Vivo Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line
KANAME SAKUMA, TOMOYUKI KII, HARUKA TAKAHASHI, SUSUMU SUZUKI, KAZUHIRO YOSHIKAWA, TETSUYA OGAWA and AKIRA TANAKA

Anticancer Research September 2022, 42 (9) 4293-4303; DOI: https://doi.org/10.21873/anticanres.15929
You have access
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab
HIDEAKI SUEMATSU, KAZUKI KANO, TAKANOBU YAMADA, ITARU HASHIMOTO, HAYATO WATANABE, KOSUKE TAKAHASHI, MAMORU WATANABE, KEI HAYASHI, YOSHIHIRO KANETA, MITSUHIRO FURUTA, YASUHIRO INOKUCHI, NOZOMU MACHIDA, TORU AOYAMA, HIROSHI TAMAGAWA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, TAKASHI OGATA and TAKASHI OSHIMA

Anticancer Research March 2022, 42 (3) 1535-1540; DOI: https://doi.org/10.21873/anticanres.15626
You have access
The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
TOMONORI HIRASHIMA, TOMOHIRO KANAI, HIDEKAZU SUZUKI, HIROKO YOSHIDA, AKANE MATSUSHITA, HIROMI KAWASUMI, YUMIKO SAMEJIMA, YOSHIMI NODA, SHINGO NASU, AYAKO TANAKA, NAOKO MORISHITA, SHOJI HASHIMOTO, KUNIMITSU KAWAHARA, YOSHITAKA TAMURA, NORIO OKAMOTO and TOSHIO TANAKA

Anticancer Research November 2019, 39 (11) 6231-6240; DOI: https://doi.org/10.21873/anticanres.13832

Main menu

User menu

Search

immune-related adverse events